文献速递神经免疫癫痫

LGI1/CASPR2抗体阳性患者扩展表型与结局:256例分析

Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG-positive patients.
PubMed 文献 · Ann Neurol · 2017-01-01

结果显示年龄>50岁是中枢神经系统受累的强预测因素,LGI1-IgG常伴疼痛、周围神经表现和发作性眩晕,初始免疫治疗97%反应良好,但9%遗留严重残疾。

要点

  • 年龄>50岁是LGI1/CASPR2抗体阳性患者中枢神经系统受累的独立预测因素。
  • LGI1-IgG阳性者常见疼痛、周围神经表现及发作性眩晕,后者常延误诊断。
  • 初始免疫治疗反应率97%,但9%患者遗留严重难治性残疾,需长期免疫和/或抗癫痫治疗。

核心结论

  • 高龄是CASPR2-IgG或LGI1-IgG血清阳性患者中枢神经系统受累的强预测因素。
  • 疼痛、周围神经表现和刻板性发作性眩晕在LGI1-IgG阳性者中常见。
  • 初始免疫治疗反应常良好,但部分患者仍严重残疾,需长期免疫治疗和/或抗癫痫药物。

研究设计与样本

  • 通过神经自身抗体检测服务识别256例LGI1-IgG和/或CASPR2-IgG血清阳性患者。

主要发现

  • 3910例受检患者中,196例LGI1-IgG阳性,51例CASPR2-IgG阳性,9例双阳性。
  • 脑脊液检测敏感性低于血清:LGI1-IgG仅检出24/38(63%),CASPR2-IgG仅检出5/6(83%)。
  • LGI1-IgG阳性标本电压门控钾通道抗体免疫沉淀值(0.33nmol/l,范围0.02-5.14)高于CASPR2-IgG阳性标本(0.10nmol/l,范围0.00-0.45,p<0.001)。
  • 以疼痛或周围神经系统表现起病的患者中39%为LGI1-IgG血清阳性(7%仅有神经病变或疼痛)。
  • 多变量分析显示年龄是中枢神经系统与周围神经系统受累的唯一显著预测因素(>50岁;比值比=15,p<0.001)。

临床怎么用

  • 对LGI1/CASPR2抗体阳性患者,尤其是年龄>50岁者,应警惕中枢神经系统受累。
  • LGI1-IgG阳性患者出现疼痛、周围神经表现或发作性眩晕时,应考虑该抗体检测以避免诊断延迟。
  • 初始免疫治疗常有效,但需长期随访识别严重难治性残疾患者并给予长期免疫和/或抗癫痫治疗。
  • 双阳性患者应筛查肿瘤,包括胸腺瘤。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe an expanded phenotypic spectrum and longitudinal outcome in 256 LGI1-IgG-seropositive and/or CASPR2-IgG-seropositive patients. METHODS: Patients were identified through service neural autoantibody evaluation. Ninety-five had longitudinal follow-up (7-456 months; median = 35). RESULTS: Among 3,910 patients tested, 196 were LGI1-IgG positive, 51 were CASPR2-IgG positive, and 9 were dual positive. Cerebrospinal fluid testing was less sensitive than serum testing, detecting only 24 of 38 (63%) LGI1-IgG-positive and 5 of 6 (83%) CASPR2-IgG-positive patients. LGI1-IgG-positive specimens had higher voltage-gated potassium channel-IgG immunoprecipitation values (0.33nmol/l, range = 0.02-5.14) than CASPR2-IgG-positive specimens (0.10nmol/l, range = 0.00-0.45, p < 0.001). Of patients presenting with pain or peripheral nervous system (PNS) manifestations, 39% were LGI1-IgG seropositive (7% had solely neuropathy or pain). Multivariate analysis identified age as the only significant predictor of central nervous system (CNS) versus PNS involvement (>50 years; odds ratio = 15, p < 0.001). Paroxysmal dizziness spells (PDS), a unique LGI1-IgG accompaniment (14% of patients), frequently delayed the diagnosis. T2-mesiotemporal hyperintensity was more common in LGI1-IgG-positive (41%) than in CASPR2-IgG-positive patients (p = 0.033). T1-bright basal ganglia were confined to LGI1-IgG-positive patients with faciobrachial-dystonic seizures (9 of 39, 31%). Cancer was found in 44% of LGI1-IgG/CASPR2-IgG dual seropositive patients (one-third thymoma). Response to initial immunotherapy was favorable in 97%; mean modified Rankin score was 3 (range = 1-5) at onset and 1.74 (range = 0-6) at last follow-up, with 9% having severe refractory disability, 20% being asymptomatic, 28% receiving immunotherapy, and 58% receiving antiepileptic medication. INTERPRETATION: Older age is a strong predictor of CNS involvement in patients seropositive for CASPR2-IgG or LGI1-IgG. Pain, peripheral manifestations, and stereotypic paroxysmal dizziness spells are common with LGI1-IgG. Response to initial immunotherapy is often favorable, but some patients remain severely disabled, requiring long-term immunotherapy and/or antiepileptic medications. Ann Neurol 2017;82:79-92.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Gadoth A, Pittock SJ, Dubey D, et al. Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG-positive patients. Ann Neurol. 2017. PMID: 28628235. doi:10.1002/ana.24979

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。